Prevymis (letermovir) - Merck (MSD)
Competitive Fitness of Cytomegalovirus Mutants Bearing Changes in the UL56 Terminase Subunit, Associated with Letermovir-Resistance, in Presence and Absence of Antivirals. (PubMed, Viruses) - Jul 29, 2026 - "Furthermore, the UL56 C325F mutant showed the highest replication capacity when grown in competition with another UL56 terminase mutant. Our results are in line with the C325F UL56 mutant being the most frequent LMV-R mutation identified in the clinic." 
Journal • Cytomegalovirus Infection • Infectious Disease
http://www.ncbi.nlm.nih.gov/pubmed/42515631
 
Graciela Andrei; Robert Snoeck; Sarah Gillemot
 
Jul 29, 2026
 
Prev Next